Major trial aims to extend life for deadly brain tumor patients

NCT ID NCT06419946

Recruiting now Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

Summary

This study is testing if adding a second chemotherapy drug, lomustine, to the standard treatment helps people with a newly diagnosed, aggressive brain tumor called glioblastoma live longer. It will involve about 200 adults with a specific tumor characteristic (MGMT promoter methylation). Participants will be randomly assigned to receive either the standard drug alone or the new two-drug combination.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Aarhus University Hospital
RECRUITING

Aarhus, Denmark

Contact Email: •••••@•••••
Gävle Hospital
RECRUITING

Gävle, Sweden

Contact Email: •••••@•••••
Haukeland University Hospital
RECRUITING

Bergen, Norway

Contact Email: •••••@•••••
Kalmar Country Hospital
RECRUITING

Kalmar, Sweden

Contact Email: •••••@•••••
Karolinska Institutet
ENROLLING_BY_INVITATION

Stockholm, Sweden
Kepler University Hospital
RECRUITING

Linz, Austria

Contact Email: •••••@•••••
Medizinische Universität Innsbruck
NOT_YET_RECRUITING

Innsbruck, Austria

Contact Email: •••••@•••••
Norrlands Universitetssjukhus, Umea, Sweden
RECRUITING

Umeå, Sweden

Contact Email: •••••@•••••
Oslo University Hospital
RECRUITING

Oslo, Norway

Contact Email: •••••@•••••
Ryhov County Hospital
RECRUITING

Jönköping, Sweden

Contact Email: •••••@•••••

Contact
Sahlgrenska University Hospital
RECRUITING

Gothenburg, Sweden

Contact Email: •••••@•••••
Skåne University Hospital
NOT_YET_RECRUITING

Lund, Sweden

Contact Email: •••••@•••••
Sorlandet Sykehus
RECRUITING

Kristiansand, Norway

Contact Email: •••••@•••••
St Olavs Hospital
NOT_YET_RECRUITING

Trondheim, Norway

Contact Email: •••••@•••••
Stavanger University Hospital
NOT_YET_RECRUITING

Stavanger, Norway

Contact Email: •••••@•••••
Sundsvall Hospital
ENROLLING_BY_INVITATION

Sundsvall, Sweden
University Hospital Graz
NOT_YET_RECRUITING

Graz, Austria

Contact Email: •••••@•••••
University Hospital St. Pölten
ENROLLING_BY_INVITATION

Sankt Pölten, Austria
Uppsala University Hospital
RECRUITING

Uppsala, Sweden

Contact Email: •••••@•••••
Örebro University Hospital
RECRUITING

Örebro, Sweden

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GLIOBLASTOMA, IDH-WILDTYPE MGMT-METHYLATED GLIOBLASTOMA